BCL2 and neoplasm: Subsequently, multiple preclinical studies demonstrated potent anti-tumor activity of menin inhibitor in vivo, paving the way for the ongoing clinical trial.29,30 Besides, menin inhibitor in combination with BCL2 inhibitors also exerted synergistic lethality in cell lines.31 These potent agents are promising to further enhance treatment effectiveness and reduce toxicity, especially for those low-risk and intermediate-risk patients in our prognostic model.